公开(公告)号：EP3236954B2

公开(公告)日：2024-09-04

申请号：EP15874302.1

申请日：2015-12-22

IPC分类号： A61K9/28 ,  A61K9/30 ,  A61K9/34

CPC分类号： A61K9/284 ,  A61K9/286 ,  A61K9/2866 ,  A61K9/4891

公开(公告)号：EP4000605A2

公开(公告)日：2022-05-25

申请号：EP20839714.1

申请日：2020-07-13

申请人： DVA Farma Mexicana S.A. de C.V.

发明人： ESCORCIA RODRÍGUEZ, Francisco ,  GARCIA MONDRAGON, Maria de Lourdes ,  FLORES NAVARRETE, Ana Karen ,  ESPITIA RODRIGUEZ, José Luis

IPC分类号： A61K9/28 ,  A61K9/30 ,  A61K9/36 ,  A61K9/50

摘要： The present document discloses compositions and procedures for applying pharmaceutical tablet coatings, recognized as film coatings wherein it is possible to obtain a final product coated with brightness superior to that achievable with typical compositions. The main difference in the composition is in the inclusion of the product derived from isomaltulose, which is a mixture of 6-O-α-D-glucopyranosyl-D-mannitol dihydrate with 6-O-α-D-glucopyranosyl-D- sorbitol, known as Isomalt, combined with a variety of film-forming polymers such as ethylene glycol and polyvinyl alcohol copolymer, copovidone, polyvinyl alcohol, and cellulosic derivatives, wherein the process conditions are advantageous as it is possible to handle high concentrations of solids in their preparation and wider applying temperature ranges than normally recommended for film coatings.

公开(公告)号：EP3442509A1

公开(公告)日：2019-02-20

申请号：EP17782788.8

申请日：2017-03-03

申请人： University of Utah Research Foundation

发明人： MUNGER, Mark A

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K9/30 ,  A61K31/135 ,  A61K31/195 ,  A61K31/216

公开(公告)号：EP2341910B1

公开(公告)日：2018-09-05

申请号：EP09825191.1

申请日：2009-10-20

申请人： Jazz Pharmaceuticals, Inc.

发明人： ROURKE, Andrea ,  ALLPHIN, Clark ,  MURPHY, Maura

IPC分类号： A61K9/20 ,  A61K9/30 ,  A61K31/19 ,  A61P25/14 ,  A61P25/26

CPC分类号： A61K31/19 ,  A61K9/2054 ,  A61K9/282 ,  A61K9/284

摘要： The present invention provides a pharmaceutical composition, presented as a solid unit dosage form adapted for oral administration of sodium oxybate. The preferred unit dosage form is a tablet comprising a relatively high weight-percentage of sodium oxybate, in combination with a relatively small weight-percentage of total excipients. This permits the tablets to contain/deliver a pharmaceutically effective amount, e.g., about 0.5-1.5 g of sodium oxybate in each tablet with a delivery profile similar to that of the liquid form. The tablets are bioequivalent to the liquid form.

公开(公告)号：EP3125872A4

公开(公告)日：2017-10-11

申请号：EP15773354

申请日：2015-03-20

申请人： HANMI PHARM IND CO LTD

发明人： SRINIVASAN SHANMUGAM ,  IM HO TAEK ,  YOON YOUNG SU ,  KIM YONG IL ,  PARK JAE HYUN ,  WOO JONG SOO

IPC分类号： A61K9/20 ,  A61K9/14 ,  A61K9/16 ,  A61K9/30 ,  A61K31/335 ,  A61K31/337

CPC分类号： A61K31/337 ,  A61K9/10 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095

摘要： Provided is an amorphous solid dispersion including a taxane or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymer, and a pharmaceutically acceptable surfactant, which has enhanced solubility. Also provided is a method for preparing the solid dispersion. The present subject matter also provides a tablet having good solubility, bioavailability and stability, which comprises the amorphous solid dispersion, an intragranular excipient, and an extragranular excipient.

公开(公告)号：EP2979698A1

公开(公告)日：2016-02-03

申请号：EP14774086.4

申请日：2014-03-28

申请人： Astellas Pharma Inc.

发明人： TAKAE Seiji ,  KOJIMA Hiroyuki ,  SAKURAI Atsushi ,  TAMURA Tetsuya ,  TASAKI Hiroaki ,  MURO Atsushi

IPC分类号： A61K31/437 ,  A61K9/20 ,  A61K9/30 ,  A61K47/10 ,  A61K47/14 ,  A61P29/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00

CPC分类号： A61K31/437 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/2806

摘要： A pharmaceutical composition containing, as the active ingredient, 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, of which the solubility in an acidic pH region is different from that in a neutral pH region, with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance, is provided. The pharmaceutical composition for oral administration of the present invention contains 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, and a hydrophilic lubricant, and is useful as a pharmaceutical composition for oral administration with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance.

摘要翻译： 含有作为活性成分的4 - {[（1R，2s，3S，5s，7s）-5-羟基-2-金刚烷基]氨基} -1H-吡咯并[2,3-b]吡啶-5 其中在酸性pH区域中的溶解度不同于在中性pH区域中的溶解度，具有快速崩解性质和快速的药物溶解性质以及预期良好的药物剂量顺应性。 本发明的口服给药用药物组合物含有4 - {[（1R，2s，3S，5s，7s）-5-羟基-2-金刚烷基]氨基} -1H-吡咯并[2,3-b] 5-甲酰胺或其药学上可接受的盐和亲水性润滑剂，并且可用作具有快速崩解性和快速药物溶解性的口服药物组合物以及期望良好的药物剂量依从性。

公开(公告)号：EP2762167A4

公开(公告)日：2015-12-09

申请号：EP11873481

申请日：2011-09-30

申请人： MOCHIDA PHARM CO LTD

发明人： KUDOU YUMIO ,  WARABINO KUNIOMI ,  ITO HIROMITSU

IPC分类号： A61K47/32 ,  A61K9/30 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38

CPC分类号： A61K9/2866 ,  A61K9/0053 ,  A61K9/2072 ,  A61K9/2813 ,  A61K9/282 ,  A61K9/2826 ,  A61K9/284 ,  A61K9/286 ,  A61K9/2886 ,  A61K31/522 ,  A61K31/5383

公开(公告)号：EP2531180A4

公开(公告)日：2014-04-02

申请号：EP11737251

申请日：2011-01-18

申请人： HANMI SCIENCE CO LTD

发明人： WOO JONG SOO ,  PARK JAE HYUN ,  KIM YONG IL ,  NA YOUNG JUN ,  KIM MIN JUNG ,  LEE YUN AH

IPC分类号： A61K9/24 ,  A61K9/22 ,  A61K9/30 ,  A61K31/137 ,  A61K31/495

CPC分类号： A61K31/495 ,  A61K9/209 ,  A61K31/137 ,  A61K2300/00

公开(公告)号：EP2561892A4

公开(公告)日：2013-09-04

申请号：EP11765698

申请日：2011-03-30

申请人： MOCHIDA PHARM CO LTD

发明人： KUDOU YUMIO ,  WARABINO KUNIOMI

IPC分类号： A61K47/32 ,  A61K9/30 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38

CPC分类号： A61K9/2866 ,  A61K9/2072 ,  A61K9/2813 ,  A61K9/2826 ,  A61K9/284 ,  A61K9/286 ,  A61K9/2886 ,  A61K31/522 ,  A61K31/5383

公开(公告)号：EP2561892A1

公开(公告)日：2013-02-27

申请号：EP11765698.3

申请日：2011-03-30

申请人： Mochida Pharmaceutical Co., Ltd.

发明人： KUDOU Yumio ,  WARABINO Kuniomi

IPC分类号： A61K47/32 ,  A61K9/30 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38

CPC分类号： A61K9/2866 ,  A61K9/2072 ,  A61K9/2813 ,  A61K9/2826 ,  A61K9/284 ,  A61K9/286 ,  A61K9/2886 ,  A61K31/522 ,  A61K31/5383

摘要： It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable preparation that does not affect dissolution property. The aforementioned object can be achieved using a coating composition comprising a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate, a polyvalent metal compound, and at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate, or using a coating composition comprising, as thickeners, hydroxypropylmethylcellulose and sugar or sugar alcohol having a solubility at 20°C of 30 or more.

摘要翻译： 本发明的目的是提供一种涂料组合物，其用于口服制剂，其施用性能得到改善，和/或不影响溶解性能的容易施用的制剂。 上述目的可以使用包含选自羧乙烯基聚合物和藻酸钠的第一增稠剂，多价金属化合物和至少一种选自黄原胶， 瓜尔胶和海藻酸钠，条件是当第一增稠剂是藻酸钠时，第二增稠剂不是藻酸钠，或者使用包含作为增稠剂的羟丙基甲基纤维素和在20℃下的溶解度为30的糖或糖醇的涂料组合物为30 或者更多。